AI in Genomics Market

Overview

The global AI in Genomics Market was valued at USD 1.4 billion in 2025 and is projected to reach USD 12.2 billion by 2034, growing at a CAGR of 27% during the forecast period (2026–2034). The market is driven by the rapid rise in clinical genome sequencing, the need for faster variant interpretation, and the use of human genetic evidence to select drug targets. Cloud platforms, GPU computing and curated knowledge bases are steadily lowering the cost of analyzing each genome. The market is shifting from conventional, standalone bioinformatics pipelines toward integrated, cloud-based platforms that combine sequencing data, curated evidence and trained models in one workflow. Sequencing vendors now embed AI inside instruments and analysis software, while specialist firms offer federated environments that keep sensitive data in place. Foundation models trained on large genome collections are replacing hand-built rules for variant effect prediction. Government initiatives such as the Emirati Reference Genome Platform, approved by the Emirates Genome Council in Abu Dhabi in May 2025 after a study of 50,000 genetic samples identified 5,296,683 novel variants, show how national programs create demand for population-specific reference data and AI-based interpretation. The Department of Health – Abu Dhabi hosts the platform and encourages clinicians and researchers to use it, which links public genomic assets directly to clinical and research analytics. Similar national efforts elsewhere are expected to widen the customer base for AI analysis vendors. By Region, North America held the largest share of the market in 2025, supported by a dense base of sequencing vendors, cloud providers, precision oncology laboratories and biopharmaceutical sponsors in the United States. Asia-Pacific is expected to be the fastest-growing region as China, Japan, South Korea and India expand clinical sequencing capacity, national genome efforts and domestic AI model development.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Foundation Models for DNA Interpretation Emerging as a Transformational Trend

• Deep learning models trained on large DNA sequence collections now predict how genetic variants change gene activity, splicing and chromatin behavior. Vendors are moving from rule-based variant filters toward learned models that rank variants by likely biological effect. This shortens the path from raw sequence to a testable hypothesis for research teams.
• Sequencing and analytics vendors are embedding machine learning directly into basecalling, consensus generation and variant detection. Instruments and software increasingly ship as tuned pairs, so accuracy gains reach customers without extra bioinformatics staff. This integration raises the entry barrier for standalone tools that lack proprietary training data and validated benchmarks.
• Hospitals and reference laboratories are adopting AI-assisted interpretation to manage growing exome and genome volumes. Automated evidence retrieval and variant ranking cut manual review time per case. Laboratories that standardize on certified platforms gain consistent reporting, which matters under European IVDR and other clinical quality requirements. Consistent outputs also help multi-site networks compare cases.
• Google DeepMind published AlphaGenome in Nature, a model that reads up to one million DNA base pairs and outperformed competing models in 25 of 26 variant effect prediction evaluations. The model weights were released for research use alongside the paper, giving vendors and academic groups a new public benchmark to test against.

KEY MARKET DRIVER

Rising Clinical Sequencing Volumes and Population Genome Programs Driving Demand for AI Analysis

• Falling sequencing costs have moved whole exome and whole genome testing from research settings into routine diagnosis of rare disease and cancer. Each additional genome adds interpretation work that manual teams cannot absorb. Laboratories therefore look to AI platforms to protect turnaround times and control staffing costs while case volumes climb.
• Biopharmaceutical companies use human genetic evidence to select drug targets, which raises demand for tools that mine large cohorts quickly. Machine learning helps separate causal signals from background variation in biobank scale data. Sponsors that adopt these tools early can build stronger target portfolios before clinical spending begins and reduce late-stage attrition.
• Regulatory acceptance of software-based interpretation is improving buyer confidence. European IVDR certification of interpretation software and CE-IVD marking of analysis modules give laboratories a compliant route to adopt AI. Vendors with certified products can win accounts that previously limited such tools to research use. Clear pathways reduce validation effort for new sites.
• England's 10 Year Health Plan, published in July 2025, proposes a Genomics Population Health Service that would use polygenic risk scores to shift National Health Service effort from treatment toward prevention. The plan also suggests a trial with Our Future Health on integrated risk scores for cardiovascular disease. Both proposals create a visible public demand signal for genomic analytics suppliers.

KEY MARKET OPPORTUNITY

AI-Enabled Target Discovery and Pharma Data Partnerships Creating New Revenue Streams

• Pharmaceutical sponsors are buying access to curated genomic datasets and trained models instead of building every asset in-house. This creates recurring licensing and data-as-a-service revenue for platform owners. Vendors with large, consented and well-annotated cohorts hold the strongest position in these negotiations. Such deals also give sponsors earlier access to new models.
• Underrepresented populations remain a gap in genomic reference data, which limits model accuracy for large parts of the world. Vendors that build ancestry-diverse references and region-specific models can serve national programs and local health systems. Such products also reduce variant misclassification in patients outside European ancestry groups and improve clinical confidence.
• Federated analysis lets hospitals, biobanks and sponsors study sensitive genomic data without moving it. Software that supports secure, governed access opens datasets that were previously out of reach. Providers of trusted research environments can charge for platform use and for compliance services around each study. Early adopters include public biobanks and multi-country research consortia.
• Illumina introduced the Billion Cell Atlas, the first tranche of a program to build a 5 billion cell genome-wide perturbation dataset over three years. AstraZeneca, Eli Lilly and Merck were named as the first users to validate genetic targets and train AI models on it, which gives the dataset immediate commercial relevance.

AI in Genomics Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Component

Software held the largest market share in 2025 because every genomics workflow, from variant calling to clinical reporting, relies on licensed analysis, interpretation and data management platforms. Laboratories prefer subscription software since it scales with test volume and can be validated once, then reused across panels, exomes and genomes. Vendors keep adding AI-based variant ranking, automated literature retrieval and report drafting, which shortens review time per case. European IVDR certification and growing cloud deployment give software buyers a compliant path to production use. Recurring license revenue and high retention keep software ahead of the other components.

Services are projected to grow at the fastest CAGR during the forecast period as many hospitals, biotechnology firms and public programs lack in-house machine learning and bioinformatics staff. Providers offer managed analysis, model fine-tuning, data harmonization and compliance support, which let customers start AI projects without long hiring cycles. Pharmaceutical sponsors increasingly outsource genetic target discovery studies that need cohort scale data handling. As national genome programs move from sequencing into clinical use, demand for validation, integration and ongoing monitoring services rises. Outcome-based contracts are also gaining acceptance, which supports faster expansion of this component.

Component categories include

• Software (Dominating Segment)
• Services (Highest CAGR Segment)
• Hardware

Analysis by Technology

Machine Learning held the largest market share in 2025 because established techniques such as supervised classification, gradient boosting and statistical models still power most commercial variant filtering, pathogenicity scoring and polygenic risk products. These methods need less computing power, are easier to explain to clinicians and regulators, and perform well on curated clinical datasets. Laboratories that must document how a result was produced favor such transparent approaches. Mature tooling and a large pool of trained data scientists keep deployment costs low across routine interpretation workflows. Large published training sets for classical models keep switching costs high.

Deep Learning is projected to grow at the fastest CAGR during the forecast period as neural networks read raw sequence directly and capture long-range regulatory patterns that classical models miss. Applications include basecalling, variant detection, non-coding variant effect prediction and single-cell analysis. GPU availability in cloud platforms and sequencing instruments has reduced training and inference costs. Open model releases from research groups give commercial vendors strong starting points for fine-tuning on proprietary data, and rising investment in genomic foundation models points to a growing share of workloads. Vendors positioned around foundation models can command premium pricing.

Technology categories include

• Machine Learning (Dominating Segment)
• Deep Learning (Highest CAGR Segment)
• Natural Language Processing
• Others

Analysis by Application

Drug Discovery held the largest market share in 2025 because pharmaceutical sponsors apply genomic evidence and machine learning at the stage where wrong target choices are most costly. Human genetics helps rank targets, flag safety risks and select patient subgroups before trials begin. Sponsors pay for dataset access, model training and analytics, which creates large, repeat contracts for platform vendors. Multi-year collaborations between sequencing, data and pharmaceutical companies confirm that target discovery remains the main commercial focus of the market. Biobank scale resources and single-cell perturbation data add further depth to these programs.

Clinical Diagnostics is projected to grow at the fastest CAGR during the forecast period as exome and genome sequencing become first-line tests for rare disease, hereditary cancer and tumor profiling. AI shortens interpretation, which is the main bottleneck in reporting. Health systems are adopting platforms that classify variants against professional guidelines and generate draft reports for specialist review. Newborn and population health programs add further volume, and vendors holding regulatory certifications are better placed to capture this demand. Cloud delivery and falling sequencing costs make adoption easier for mid-sized centers.

Application categories include

• Drug Discovery (Dominating Segment)
• Clinical Diagnostics (Highest CAGR Segment)
• Population Genomics
• Agricultural Genomics
• Others

Analysis by End User

Biopharmaceutical Companies held the largest market share in 2025 because they carry the highest research budgets and the strongest commercial reason to use AI for target selection, biomarker discovery and patient stratification. These organizations buy software, data and analytics services at scale and often sign multi-year agreements with technology partners. Access to large genomic cohorts and computing capacity is a competitive asset, so sponsors invest in both internal teams and external platforms. Regulatory interest in biomarker-guided development also encourages early genomic evidence generation. Dedicated informatics teams further speed adoption within large sponsors.

Healthcare Providers are projected to grow at the fastest CAGR during the forecast period as hospitals and health systems bring genomic testing in house instead of sending samples to central laboratories. In-house testing needs software that automates variant interpretation and reporting for small teams. Academic medical centers are adopting AI platforms for oncology and rare disease services, and integrated health networks are linking genomic results to electronic records. Cloud delivery lowers the capital cost of entry, which allows mid-sized hospitals to join precision medicine programs. Training programs for clinical geneticists are also improving staff readiness.

End User categories include

• Biopharmaceutical Companies (Dominating Segment)
• Healthcare Providers (Highest CAGR Segment)
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

AI in Genomics Market Share 2025, (CAGR)

North America

45%

South America

xx%

Europe

25%

Middle East Africa

xx%

Asia Pacific

xx%

North America held the largest market share in 2025. The United States leads regional adoption through investments in genomic research, precision medicine, and AI-enabled healthcare, supported by advanced biotechnology infrastructure and collaborations between research institutions and technology providers. AI applications are increasingly used to analyze genomic data, identify disease-associated variants, support cancer research, and accelerate drug discovery. Canada contributes through genomics research programs and the adoption of computational tools in academic institutions and clinical laboratories. Established healthcare infrastructure, access to advanced computing resources, and growing demand for personalized medicine are supporting the region's leading position in the AI in genomics market.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, supported by expanding genomic research capabilities, increasing healthcare digitization, and rising investment in precision medicine. China is advancing large-scale genomic research and AI applications in disease analysis, while Japan is incorporating genomic technologies into cancer research and personalized treatment development. South Korea is strengthening its biotechnology and computational research capabilities, creating opportunities for AI-driven genomic analysis. India is expanding genomic research through national initiatives and increasing the use of advanced diagnostics. Growing sequencing capacity, larger genomic datasets, and investments in biotechnology infrastructure across these countries are expected to accelerate regional market growth.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• United Kingdom (Largest Country Market)
• Germany
• France
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• United Arab Emirates (Largest Country Market)
• Saudi Arabia (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The AI in Genomics Market is fragmented, with no single vendor controlling more than a small portion of spending across software, services and computing hardware. Sequencing leaders such as Illumina, PacBio and Oxford Nanopore embed AI in instruments and analysis software, while specialists such as SOPHiA GENETICS, QIAGEN and DNAnexus compete on interpretation and data platforms. Clinical laboratories including Tempus AI, Caris Life Sciences and GRAIL compete through proprietary data and AI-enabled tests, and AWS and NVIDIA supply cloud and GPU infrastructure. Key success factors are proprietary training data, validated accuracy, regulatory certification and close integration with sequencers. Leading companies are prioritizing cloud-native platforms, foundation models and pharmaceutical data partnerships, with innovation focused on agentic analysis, federated access and multimodal data. Partnerships between instrument and software vendors, and acquisitions of interpretation software, continue to reshape the field.

Key Players

• Illumina, Inc. (US)
• NVIDIA Corporation (US)
• Tempus AI, Inc. (US)
• SOPHiA GENETICS SA (Switzerland)
• Amazon Web Services, Inc. (US)
• QIAGEN N.V. (Netherlands)
• DNAnexus, Inc. (US)
• Caris Life Sciences, Inc. (US)
• PacBio (US)
• Oxford Nanopore Technologies plc (UK)
• BGI Genomics Co., Ltd. (China)
• GRAIL, Inc. (US)
• Genomics plc (UK)
• Genomenon, Inc. (US)
• Lifebit (UK)

Recent Market Developments

• In January 2026, Lifebit released version 4 of its platform, described as the first fully agentic federated trusted research environment, at the J.P. Morgan Healthcare Conference. Researchers can query sensitive biomedical and genomic data through natural language while the data stays at its source. The release gives sponsors, biobanks and public programs a governed route to AI analysis without moving patient data.
• In April 2026, SOPHiA GENETICS announced that Mount Sinai Health System will adopt the SOPHiA DDM Platform for blood cancer and solid tumor testing, joining a network of more than 990 institutions. The adoption shows academic medical centers moving to AI-enabled interpretation to cut hands-on analysis time and improve turnaround in oncology testing.
• In May 2026, PacBio began shipping SPRQ-Nx sequencing chemistry and multi-use SMRT Cells for the Revio platform worldwide, with improved DeepConsensus and expanded methylation calling. The company states that the new cells cut sequencing cost by 30% compared with the previous SPRQ chemistry. Lower-cost, higher-accuracy long-read data widens the supply of training data for genomic AI models.
• In May 2026, Caris Life Sciences reported the launch of Caris MI Clarity, a prognostic tool that uses multimodal AI and computational pathology for early-stage, hormone receptor positive, HER2 negative breast cancer in postmenopausal, node-negative patients. The product layers AI on whole exome and whole transcriptome profiling and shows laboratories extending test menus with AI-derived prognostic outputs.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is AI in Genomics?

2

What is the CAGR of the AI in Genomics Market?

3

Which component leads the AI in Genomics Market?

4

Which application dominates the AI in Genomics Market?

5

Which technology holds the highest market share?

6

What are the latest trends in the AI in Genomics Market?

7

Who are the end users of AI in Genomics?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates